Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sBOM:544742 +5.09%14 ROA % is 0.33% as of Sep. 2025, which is 92% below its 10-year median of 3.96. GuruFocus rates BOM:544742 with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Sai Parenteral's ranks worse than 62.9% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sai Parenteral's's annualizedNet Income for the quarter that ended in Sep. 2025 was ₹33 Mil.
Sai Parenteral's's average Total Assets over the quarter that ended in Sep. 2025 was ₹10,044 Mil. Therefore, Sai Parenteral's's annualized ROA % for the quarter that ended in Sep. 2025 was 0.33%.
The historical rank and industry rank for Sai Parenteral's's ROA % or its related term are showing as below:
BOM:544742'
s ROA % Range Over the Past 10 Years
Min: 0.16 Med: 3.96 Max: 4.19
Current: 0.16
During the past 3 years, Sai Parenteral's's highest ROA % was 4.19%. The lowest was 0.16%. And the median was 3.96%.
BOM:544742's ROA % is ranked worse than 62.9% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.565
vs BOM:544742: 0.16
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sai Parenteral's ROA % Related Terms
Sai Parenteral's ROA % Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's ROA % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
ROA %
3.27
4.19
3.96
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
ROA %
0.00
0.00
0.00
0.33
BOM:544742 vs LLY, JNJ, ABBV: ROA % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's ROA % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Sep. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sai Parenteral's (BOM:544742) has a ROA % of 0.33% as of Sep. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sai Parenteral's and its competitors. This is 92% below median its historical median of 3.96. Over the past decade, Sai Parenteral's' ROA % has ranged from 0.16 to 4.19. According to the industry distribution chart, Sai Parenteral's ranks #634 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is Sai Parenteral's' ROA % too high?
Sai Parenteral's' current ROA % of 0.33% is 92% below median its 10-year median of 3.96. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 4.19. The Drug Manufacturers industry median ROA % is 2.57. Sai Parenteral's' value of 0.33% is 87.1% below this industry median. Based on the distribution chart, Sai Parenteral's ranks #634 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #634 out of 1008 companies for ROA %. This places Sai Parenteral's in the lower half of its industry. The industry median ROA % is 2.57. Sai Parenteral's' value of 0.33% is 87.1% below this benchmark. Historically, Sai Parenteral's' own ROA % has ranged from 0.16 to 4.19 over the past decade. While the company's 10-year median is 3.96 vs. the industry median of 2.57, Sai Parenteral's has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.57, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current ROA % of 0.33% is 87.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current ROA % is 0.33%, which is 92% below median its own 10-year median of 3.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (BOM:544742) has a current ROA % of 0.33%. The current ROA % is 0.33%, which is 92% below median its 10-year median of 3.96 and 87.1% below the Drug Manufacturers industry median of 2.57. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sai Parenteral's (BOM:544742), the current ROA % is 0.33% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for BOM:544742
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544742 has been successfully added to your 
